AstraZeneca plc AZN announced that the European Commission (EC) has approved a label expansion of its diabetes drug, Forxiga (dapagliflozin). Forxiga has been approved for the treatment of type-1 ...

Astrazeneca Korea Co. Ltd. will pull its blockbuster diabetes drug, Forxiga (dapagliflozin), from the South Korean market, a company official confirmed to BioWorld, citing “multiple factors” like ...

(RTTNews) - AstraZeneca Plc. (AZN.L, AZN) Thursday announced that its Forxiga (dapagliflozin) has been approved in the European Union for the treatment of symptomatic chronic heart failure with ...

AstraZeneca and Bristol-Myers Squibb have pulled their diabetes drug Forxiga (dapagliflozin) from pharmacy shelves in Germany after failing to reach an agreement on price. AstraZeneca and ...

AstraZeneca plc AZN announced that Japan’sMinistry of Health, Labour and Welfare (MHLW) has granted approval to expand the label of Forxiga for the treatment of chronic heart failure with reduced ...

In a shocking, yet low-key, announcement, the sodium-glucose transporter 2 (SGLT2) inhibitor dapagliflozin (Forxiga, AstraZeneca) has been withdrawn from the market in all EU countries for the ...

(RTTNews) - AstraZeneca (AZN, AZN.L) announced Forxiga has been approved in the European Union to extend the indication for heart failure with reduced ejection fraction to cover patients across the ...

The EMA's approval of Forxiga for chronic kidney disease gives AstraZeneca access to millions of patients in the EU. Forxiga's efficacy and this massive potential market should help the label ...